SLU-PP-332

SLU-PP-332 is a non-peptide compound investigated for exercise-like metabolic signaling and endurance. Estrogen-related receptors are central to this research. It has no FDA approval and is not a GLP-1 peptide.

• Weight Loss

  Most effective

  Weight-management research examines substantial reductions in body weight and whether these persist.

• Blood Sugar Control

  Most effective

  Metabolic research evaluates improved glucose regulation and lower A1C in type 2 diabetes.

• Cardiovascular Health

  Effective

  Cardiovascular investigation concerns the potential to reduce events in people at high risk.

• Metabolic Syndrome

  Effective

  Research considers improvements across several features of metabolic syndrome together.

• Other GLP-1 Agonists (e.g. Semaglutide + Tirzepatide)

  Avoid

• Insulin

  Monitor

• Sulfonylureas

  Monitor

• Metformin

  Compatible

• SGLT2 Inhibitors

  Compatible

• Oral Contraceptives

  Caution

• Warfarin / Blood Thinners

  Monitor

• NAD+

  Compatible

Diluent: Use only bacteriostatic water; avoid saline because precipitation can occur.

1. Let your refrigerated SLU-PP-332 vial stand for 15–20 minutes so it reaches room temperature before mixing.
2. Disinfect the rubber stopper using an alcohol swab. Wait for all of the alcohol to air-dry.
3. Measure the calculated bacteriostatic water volume with a sterile syringe. Use BAC water only; saline can lead to precipitation.
4. Deliver the water slowly against the vial’s inner wall. Keep the stream from striking the powder directly.
5. Mix by gently rotating the vial in circles. Avoid vigorous shaking, which can break down the peptide.
6. Wait 2–3 minutes until dissolution is complete. Inspect the liquid for a clear appearance without color.
7. Measure your calculated dose in an insulin syringe for administration beneath the skin.
8. Choose your abdomen, upper arm or thigh for subcutaneous administration. Change sites between injections to help prevent lipodystrophy.
9. Keep the mixed vial at 2–8 °C in the refrigerator. Use the solution within 28 days of preparation.

Week 1–2

Appetite may begin to diminish. Early adjustment can include mild nausea or a feeling of fullness.

Week 2–4

Smaller portions and fewer cravings may become noticeable, along with early changes in weight.

Week 4–8

More pronounced appetite control and steady weight reduction may coincide with improved glucose levels where relevant.

Week 8–16

Larger reductions in weight and improved energy may occur as metabolic measurements begin to change.

Week 16–24

Later expectations include major weight-loss milestones, cardiovascular benefits and a more favorable lipid profile.

Week 24+

The anticipated later phase includes the largest effect and sustained, broader metabolic improvements; this is not an individual outcome guarantee.

• Nausea that is generally short-lived and related to dose · Most common
• Constipation or diarrhea as doses increase
• Vomiting, particularly during initiation or after a dose increase
• Less appetite and an earlier feeling of fullness
• Bruising or redness around the injection area
• Tiredness, particularly during the initial weeks
• Pancreatitis; stop use at once if severe abdominal pain occurs · Rare
• Effects involving thyroid C cells · Rare

Contraindications

• Avoid use if you have MEN2 or a previous thyroid cancer diagnosis.

SLU-PP-332: not approved in the US.

• US

  Not approved

  FDA — SLU-PP-332 has no approved indication and remains a research compound. No prescription pathway is identified; telehealth prescribing is not applicable.

  Rx required

  No

  Telehealth

  N/A

1. An exercise-inducible metabolite that increases endurance via the ERRγ pathway (2023)

2. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. (2024)

   PMID 37739806DOI 10.1124/jpet.123.001733

3. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. (2026)

   PMID 41850449DOI 10.1016/j.ijbiomac.2026.151450